Applied Mergers and Acquisitions. Robert F. Bruner. Читать онлайн. Newlib. NEWLIB.NET

Автор: Robert F. Bruner
Издательство: John Wiley & Sons Limited
Серия:
Жанр произведения: О бизнесе популярно
Год издания: 0
isbn: 9781118436349
Скачать книгу
In comparison with a contractual relationship, an alliance is typically more complicated and expresses a more serious commitment between the parties. A contract may formalize the alliance. But it is the exchange of managerial talent, resources, capabilities, and possibly even equity investment that elevates the alliance beyond a mere contractual agreement. An equity investment under the alliance may be structured across a range of possible deals, including a joint venture or minority investment.

      JOINT VENTURE A joint venture (JV) creates a separate entity in which your firm and the counterparty will invest. The JV agreement between the venture partners specifies investment rights, operational responsibilities, voting control, exit alternatives, and generally the allocation of risks and rewards. The entity could be a division carved out of one of the venture partners, or an entirely new business established for the venture. The agreement for large JVs may be as complicated as for an acquisition.

      MINORITY INVESTMENT Here, your firm invests directly in the counterparty firm, rather than in an intermediate firm (like the joint venture). Sometimes firms take mutual minority interests in each other; this is called a cross-shareholding arrangement and is common among large Japanese and Continental European firms. Taking a direct equity interest in another firm is a strong signal of commitment and participation in the fortunes of that firm.

      Research Findings about Joint Ventures, Alliances, and Minority Equity Investments

image

      Source of data: Thomson Financial SDC, Platinum Joint Ventures Database.

      Lerner, Shane, and Tsai (2003) studied R&D ventures formed by small biotechnology firms. They found that when external equity financing is unavailable or limited in supply, these firms are more likely to fund their R&D by organizing research JVs with large corporations. And the agreements structured under these circumstances tend to assign the bulk of control to the large corporate partner. Such agreements are likely to be renegotiated and to be significantly less successful than others. Robinson and Stuart (2002) found that the staging of investment is ubiquitous between small biotechnology R&D firms and their partners. Staging releases investment funds as the R&D firm passes preset milestones—this is discussed in more detail in Chapter 14.

       Buyers have good investment opportunities. Chen et al. (2000) find that where the buyer has a good record of investment returns, the announcement of a JV is associated with gains to shareholders. But where the buyer’s record is weak, the JV announcement could be taken as a signal of pessimism about the buyer’s internal opportunities.

       JV increases focus for the buyer. Ferris et al. (2002) find materially better returns for buyers where the JV increases the business focus of the firm.

       JV reduces agency costs. Allen and Phillips (2000) concluded that intercorporate equity investments in the form of JVs, alliances, and minority stakes reduced “the costs of creating, expanding, or monitoring the alliances or ventures between firms and their corporate block holders.” (Page 2813) Robinson (2001) argued that JVs help to shelter “underdog” projects from the adverse behavior sometimes found in internal capital markets (e.g., winner-picking). Allen and Phillips (2000) found that the returns from JVs and alliances were greatest in the instance of R&D intensive industries. These gains may stem from alleviating the problems of information asymmetries arising from the development of new technology.

       JV is in a favorable foreign environment, in terms of laws and regulations. Returns from JVs vary by country and region, consistent with the discussion in Chapter 5 that variations in deregulation and rule of law will affect investment returns.

Study Cumulative Abnormal Returns at the Event Cumulative Abnormal Returns after the Event Sample Size Sample Period Notes
Gleason, Mathur, Wiggins (2003) 638 311 197 134 376 1985–1998 Sample of deals involving financial services institutions.
Ferris et al. (2002) +0.52%* whole sample +0.71%* focus-increasing JVs 0.11% focus-decreasing JVs (all estimates are around days –1,0) +5.31% whole sample +9.43%

e-mail: [email protected]